REXAHN PHARMACEUTICALS INC's ticker is RNN and the CUSIP is 761640101. A total of 38 filers reported holding REXAHN PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $6,000 | -33.3% | 44,878 | 0.0% | 0.00% | – |
| Q3 2016 | $9,000 | -18.2% | 44,878 | 0.0% | 0.00% | – |
| Q2 2016 | $11,000 | -26.7% | 44,878 | 0.0% | 0.00% | – |
| Q1 2016 | $15,000 | -6.2% | 44,878 | 0.0% | 0.00% | – |
| Q4 2015 | $16,000 | -30.4% | 44,878 | 0.0% | 0.00% | – |
| Q3 2015 | $23,000 | -14.8% | 44,878 | 0.0% | 0.00% | – |
| Q2 2015 | $27,000 | +3.8% | 44,878 | +24.1% | 0.00% | – |
| Q1 2015 | $26,000 | +4.0% | 36,171 | 0.0% | 0.00% | – |
| Q4 2014 | $25,000 | -13.8% | 36,171 | 0.0% | 0.00% | – |
| Q3 2014 | $29,000 | -6.5% | 36,171 | 0.0% | 0.00% | – |
| Q2 2014 | $31,000 | -20.5% | 36,171 | 0.0% | 0.00% | – |
| Q1 2014 | $39,000 | +333.3% | 36,171 | +111.7% | 0.00% | – |
| Q4 2013 | $9,000 | +12.5% | 17,083 | 0.0% | 0.00% | – |
| Q3 2013 | $8,000 | 0.0% | 17,083 | 0.0% | 0.00% | – |
| Q2 2013 | $8,000 | – | 17,083 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Anson Funds Management LP | 18,340,000 | $3,852,000 | 0.41% |
| SABBY MANAGEMENT, LLC | 9,464,849 | $1,988,000 | 0.07% |
| Northeast Financial Consultants Inc | 150,000 | $31,000 | 0.01% |
| HUDSON VALLEY INVESTMENT ADVISORS INC /ADV | 200,000 | $42,000 | 0.01% |
| TWO SIGMA SECURITIES, LLC | 185,239 | $39,000 | 0.01% |
| Benin Management CORP | 93,000 | $20,000 | 0.01% |
| CONDOR CAPITAL MANAGEMENT | 145,000 | $30,000 | 0.01% |
| NIXON PEABODY TRUST CO | 10,000 | $2,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 47,677 | $10,000 | 0.00% |
| Renaissance Technologies | 3,201,993 | $672,000 | 0.00% |